Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $2.15 0.1500 +7.50%
AGIO $48.63 2.2800 +4.92%
ARGS $8.82 0.3600 +4.26%
VSTM $9.64 0.2900 +3.10%
MDVN $100.93 2.9700 +3.03%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ECYT $7.64 -0.5200 -6.37%
RDHL $13.35 -0.8500 -5.99%
MEIP $6.63 -0.3700 -5.29%
CBMG $20.40 -1.1000 -5.12%
IMUC $0.92 -0.0494 -5.09%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Cut-Price GSK Skin Cancer Drug Wins Nice Approval

(The Telegraph [UK]) Sept 18, 2014 - A skin cancer drug developed by GlaxoSmithKline will be available through the NHS after the company agreed to a secret discount.
read article 

Merck KGaA Seeks Partner For Immuno-Oncology Drug by Year-End

(Reuters) Sept 18, 2014 - German drugs and chemicals maker Merck KGaA is in advanced talks with potential partners interested in its experimental cancer immunotherapy drug and expects to clinch a partnership deal before the end of the year.
read article 

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

(TheStreet) Sept 17, 2014 - The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
read article 

Nektar Anticipates a Big Payday

(San Francisco Chronicle) Sept 16, 2014 - Nektar Therapeutics in San Francisco is anticipating big paydays from its partner AstraZeneca after a treatment they co-developed won approval Tuesday for opioid-induced constipation.
read article 

Roche CEO Rules Out Big Deals

(Wall Street Journal) Sept 17, 2014 - Roche won't change its acquisition strategy following the recent spate of megadeals signed or abandoned in the pharmaceutical sector, Chief Executive Severin Schwan said in an interview.
read article (paid subscription required) 

Auxilium Adds Poison Pill Against Endo's $2.2B Offer

(Bloomberg) Sept 17, 2014 - Auxilium Pharmaceuticals Inc. adopted a so-called poison pill shareholder rights plan to try and fend off an unsolicited, $2.2 billion offer from Endo International Plc, a maker of pain drugs.
read article 

Hospitals and Insurer Join Forces in California

(New York Times) Sept 17, 2014 - In a partnership that appears to be the first of its kind, Anthem Blue Cross, a large California health insurance company, is teaming up with seven fiercely competitive hospital groups to create a new health system in the Los Angeles area.
read article 

Obama: U.S. Ready to Take the Lead in Ebola Fight

(CNN) Sept 16, 2014 - After an in-person briefing from the staff at the Centers for Disease Control and Prevention in Atlanta, President Barack Obama on Tuesday announced a "major increase" in the U.S. response to the Ebola outbreak in West Africa.
read article 

Health Care for Britain in Harsh Light

(New York Times) Sept 16, 2014 - The decision by a 5-year-old’s parents to take him to the Czech Republic for treatment of a brain tumor has thrown a harsh light on Britain’s National Health Service.
read article 

Takeda Puts Oncology Unit in Cambridge

(Boston Globe) Sept 16, 2014 - The companywide reorganization will include a strong focus on its cancer drug business in Cambridge.
read article (free registration required) 

Penn Medicine and Wistar Receive $12 Million NCI Melanoma Grant to Help Fast Track Lab Discoveries into Treatments

(Penn Medicine) Sept 17, 2014 - Melanoma physicians and researchers from Penn Medicine and The Wister Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute.
read press release 

Lilly Sells Failed Cancer Drug Enzastaurin to Denovo

(PharmaTimes [UK]) Sept 16, 2014 - Eli Lilly has sold enzastaurin, a cancer treatment it abandoned development on, to San Diego-based Denovo Biopharma.
read article 

EMD Serono Teams Up with Sutro Biopharma to Work on Antibody Drug Conjugates

(Boston Globe) Sept 17, 2014 - EMD Serono Inc., a Rockland-based subsidiary of Germany’s Merck KGaA, and Sutro Biopharma said Wednesday that they have agreed to collaborate on developing antibody drug conjugates that target such diseases as cancer.
read article (free registration required) 

Sprague Study Estimates Number of U.S. Women with Mammographically-Dense Breasts

(University of Vermont) Sept 15, 2014 - A new study published in the September 2014 Journal of the National Cancer Institute (JNCI) estimates the number of women in the United States for whom breast density notification legislation would potentially impact.
read article 

ASCO 50th Anniversary Poll Names the Top 5 Advances from the Past 50 Years

(ASCO) Sept 17, 2014 - The American Society of Clinical Oncology (ASCO) today announced the “Top 5 Advances in 50 Years of Modern Oncology,” based on results of worldwide voting on CancerProgress.Net – ASCO’s interactive website documenting the history of progress against cancer.
read press release 

Oncolytics Biotech® Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

(Yahoo! Finance) Sept 16, 2014 - Oncolytics Biotech® Inc. today announced overall and KRAS-mutated patient data from a two-arm randomized phase 2 study of carboplatin, paclitaxel plus REOLYSIN® (test arm) versus carboplatin and paclitaxel alone (control arm) in the first line treatment of patients with recurrent or metastatic pancreatic cancer (NCI-8601).
read article 

Novartis Presents Oncology Research Advances with New Data on Zykadia(TM), Afinitor® and Key Pipeline Compounds at ESMO 2014

(NASDAQ) Sept 17, 2014 - Latest Zykadia data in patients with ALK+ non-small cell lung cancer, including updated brain metastases analysis from pivotal trial; final overall survival data from Phase III trial of Afinitor in advanced pancreatic neuroendocrine tumors (pNET); findings on Novartis pipeline compounds that target underlying cause of key diseases, including breast cancer, advanced basal cell carcinoma and melanoma.
read article 

Roche to Present Latest Oncology Advances During ESMO 2014 Congress

(Roche) Sept 17, 2014 - Presentations will include results from the Phase III coBRIM study of Roche’s investigational MEK inhibitor cobimetinib plus Zelboraf compared to Zelboraf alone, potentially paving the way for a new standard of care; final survival data from the Phase III CLEOPATRA study of the combination of Perjeta, Herceptin and chemotherapy, further confirming the potential of this regimen for people with HER2-positive metastatic breast cancer; and more.
read corporate press release 

Novel Drug Targeting Leukemia Cells Enters Clinical Trial

(UC San Diego Health System) Sept 16, 2014 - Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.
read press release 

Study Offers Clues to How Breast Implants May Cause Lymphoma

(University of Cambridge [UK]) Sept 16, 2014 - Researchers at the University of Cambridge have identified clues to explain how breast implants may, on very rare occasions, contribute to the development of lymphoma.
read article 

Genetic Discovery Yields Prostate Cancer Test, Promise of Future Therapy

(UPMC) Sept 15, 2014 - A genetic discovery out of the University of Pittsburgh School of Medicine is leading to a highly accurate test for aggressive prostate cancer and identifies new avenues for treatment.
read press release 

Study: New Radiosurgery Technology Provides Highly Accurate Treatment

(Henry Ford Health System) Sept 16, 2014 - A new stereotactic radiosurgery system provides the same or a higher level of accuracy in targeting cancer tumors – but offers greater comfort to patients and the ability to treat multiple tumors at once – when compared to other radiation therapy stereotactic systems.
read press release 

Study Adds to Cancer-fighting Promise of Combined Immunotherapy-radiation Treatment

(Science Codex) Sept 15, 2014 - A study in mice implanted with breast and melanoma cancers adds to a growing body of evidence that highly focused radiation – long thought to suppress immunity – can actually help boost the immune system's fight against cancer when combined with a new kind of immune-enhancing drug.
read article 

Fox Chase Study Helps Identify When and How Much Various Prostate Cancer Treatments will Impact Urinary and Sexual Functioning

(FCCC) Sept 16, 2014 - Men with prostate cancer may one day be able to predict when and how much various treatments will impact their urinary and sexual functioning, thanks in part to new findings presented at ASTRO.
read press release 

Fox Chase Study Questions the Benefit of Endocrine Therapy in Elderly Women with Low Risk Hormone Receptor Positive Breast Cancer

(FCCC) Sept 16, 2014 - Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer.
read press release